Science Corp. Raises $230M, Preps Brain Sensor Trials — SkimNews
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Science Corporation completed a $230 million Series C round last month, valuing the company at $1.5 billion.
- Dr. Murat Günel, chair of Yale Medical School’s Department of Neurosurgery, joined Science as a scientific adviser to lead its first U.S. human trials of the biohybrid brain‑computer interface.
- PRIMA, Science’s most advanced product, is a vision‑restoring implant for macular degeneration that the company plans to launch in Europe after regulatory approval, possibly as soon as this year.
- Science is developing a biohybrid sensor that embeds lab‑grown neurons capable of optical stimulation and designed to integrate naturally with a patient’s brain tissue.
- The sensor will be implanted inside the skull, resting on top of the cortex, and contains 520 recording electrodes roughly the size of a pea.
- The initial trial will enroll patients already undergoing craniectomy, such as stroke victims, to test safety and efficacy of the sensor without embedded neurons.
- Dr. Günel said it would be optimistic to expect human trials before 2027, indicating the technology remains early‑stage.
Why it matters: The $230 million infusion and the appointment of a top Yale neurosurgeon give Science a credible path to human testing, potentially accelerating the transition from animal prototypes to clinical applications and positioning the firm ahead of competitors like Neuralink in the emerging biohybrid BCI market.
Ask SkimNews
